UNITED THERAPEUTICS Corp (UTHR)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$1,279.7M
Cash & Equivalents
$463.3M
Quarterly Burn Rate
$24,059M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04285086 Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Into... PHASE3 Active Not Recruiting 174

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for UTHR.

SEC EDGAR Filings

All SEC filings for UNITED THERAPEUTICS Corp on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.